Link Between Driver of Ovarian Cancer and Metabolism Opens Up New Therapeutic Strategies

January 11, 2021 3:00 pm

Loss of ARID1A causes increased glutamine metabolism, which can be blocked pharmacologically to target ARID1A-mutant tumors.

Mutations that inactivate the ARID1A gene in ovarian cancer increase utilization of the glutamine amino acid making cancer cells dependent on glutamine metabolism, according … Read more

‘Virtual Biopsies’ Could Replace Tissue Biopsies in Future Thanks to Technique Developed by Cambridge Scientists

January 6, 2021 5:00 am

A new advanced computing technique using routine medical scans to enable doctors to take fewer, more accurate tumour biopsies, has been developed by cancer researchers at the University of Cambridge. This is an important step towards precision tissue sampling for

Read more

Proper Staging of Early-Stage Ovarian Cancer Before Treatment Provides Critical Information for Potentially Improved Outcomes

January 5, 2021 6:00 am

A gynecologic oncology expert from the University of California, Davis reviewed early-stage ovarian cancer and the importance of knowing what options are available before, during and after treatment.

By

Although patients diagnosed with early-stage ovarian cancer can … Read more

PARP Inhibitors Linked With Blood Cancer Risk

December 28, 2020 11:00 am

Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden

By Leah Lawrence

Although rare, poly-ADP ribose polymerase (PARP) inhibitors were associated with an increased risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and occurred even … Read more

CURE Media Group Bolsters Strategic Alliance Partnership Program With 12 New Partners

December 18, 2020 1:00 pm

The Clearity Foundation is proud to announce its partnership with CURE Media Group, opening up many opportunities for us to reach more women and families who can directly benefit from our services. Specifically, having Clearity’s ovarian cancer experts participate in

Read more

Phase 1 Study of Novel Drug for Ovarian Cancer Shows Positive Results

December 5, 2020 6:00 pm

One patient had a complete response and the majority of patients achieved disease control at 12 weeks.

A phase 1 trial of an anti-folate receptor alpha (FolRα) human immunoglobulin G1 (IgG1) antibody for women with advanced ovarian cancer showed responses

Read more

SEngine Precision Medicine IDs Potential Ovarian Cancer Treatment Combos Using Organoid Approach

November 23, 2020 8:00 pm

By Caroline Hopkins

Using organoids that closely model certain features of ovarian tumors, researchers have identified and tested treatment combinations that may benefit patients, many of whom experience acquired or de novo resistance to PARP inhibitors.

In a study recently … Read more

New Combination Treatment for Recurrent Ovarian Cancer Shows Positive Outcomes

November 19, 2020 5:00 pm

A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.

In a new article in JAMA Oncology, the … Read more

Revolutionary CRISPR-Based Genome Editing System Treatment Destroys Cancer Cells

November 18, 2020 4:00 pm

TAU breakthrough may increase life expectancy in brain and ovarian cancers.

Researchers at Tel Aviv University (TAU) have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers, a significant step on the way to finding a cure … Read more

‘Next-Gen’ Immunotherapy Active in Advanced Cancers

November 16, 2020 5:00 pm

Disease control in two-thirds of patients treated with bispecific antibody.

By Charles Bankhead

An investigational drug that combines PD-1/L1 inhibition and T-cell stimulation led to disease control in two-thirds of patients with unresectable advanced solid malignancies, a preliminary clinical study … Read more

The Stressful Conclusion of a Clinical Trial

November 9, 2020 9:00 am

By 

When I learned this summer that the clinical trial of the cancer drug that seems to be keeping me alive had unexpectedly shut down, I discovered the murky rules governing drug trials and the stressful confusion they … Read more

SRS Instead of WBRT for Patients With Multiple Brain Metastases

October 29, 2020 3:00 pm

 Roxanne Nelson, RN, BSN

Stereotactic radiosurgery (SRS) should replace whole-brain radiotherapy (WBRT) as the new standard of care for patients with four or more brain metastases, say researchers who report results from a randomized trial conducted in patients with … Read more

ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer

October 28, 2020 4:00 pm

By Andrew D. Bowser

New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC). However, trials investigating retreatment are underway, so this recommendation may change.

The guidelines, from … Read more

KSQ Boosts PARP Inhibition In Models Of Cancer With USP1 Inhibitor

October 27, 2020 7:00 pm

KSQ Therapeutics is hoping to provide hope for ovarian and breast cancer patients that have developed a resistance to drugs and those who don’t respond at all by developing a drug that may be able to boost the effectiveness of … Read more

Adagrasib a Promising New Treatment for Lung, Pancreatic, Endometrial, Ovarian and Colon Cancers

October 27, 2020 6:00 pm

By Mary Moore

A new drug that inhibits a cancer mutation in the KRAS gene has shown encouraging results in patients with lung cancer, colon cancer, and other solid tumors.

For decades, scientists have been trying to develop new … Read more

New BRAF Inhibitor Cancer Drug Shows Efficacy

October 26, 2020 4:00 pm

By Robert Dillard

A new drug developed to treat cancers with an altered BRAF gene has shown efficacy in an early patient trial, according to a study presented at the 32nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, … Read more

Triple therapy Shows Promise in Non-Germline BRCA-Mutated Ovarian Cancer

October 10, 2020 5:00 pm

By Savannah Demko

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

“Preclinical studies suggest the potential for synergy between … Read more

Bayer’s ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest

September 29, 2020 4:00 pm

Researchers are optimistic that data from a first-in-human clinical trial of Bayer’s ATR-inhibiting agent, BAY-1895344, may pave the way for a new class of precision oncology treatments for patients with certain DNA damage response (DDR) defects in their tumors.

The … Read more

FDA Grants Expanded Access Program to Ulixertinib for MAPK Pathway Aberrant Cancer

September 29, 2020 3:00 pm

By Matthew Fowler

xCures recently announced that the FDA granted its IND immediate Expanded Access Program for the ERK inhibitor ulixertinib to treat patients with MAPK pathway aberrant cancer.

The FDA granted the investigational new drug application for the ERK

Read more

Halting Cancer by Halting DNA Repair

September 25, 2020 11:00 am

By Liam Drew

PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could expose a weak … Read more